Drug intelligence / Profile preview

EuHZV

Development stage: Phase 1
Lead developer: EuBiologics
Modality: Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

EuHZV is a protein-based vaccine candidate designed for the prevention of shingles (herpes zoster), chickenpox (varicella-zoster infection), and herpes simplex infections. It consists of a vaccine antigen displayed on immunogenic nanoparticles, utilizing POP BIO's spontaneous nanoparticle display technology. The vaccine is currently being evaluated in Phase 1 clinical trials in healthy adults aged 50 to 69 years. The primary goal is to induce immunity against varicella-zoster virus (VZV), which causes both chickenpox and shingles, by presenting viral antigens in a highly immunogenic format. EuHZV is being developed through a collaboration between POP BIO and EuBiologics.

Other names: EuCorVac-HZV

Targets

gE (VZV glycoprotein E)

Beyond the preview

Go deeper on EuHZV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EuHZV.

Explore the full profile